Alcaligenes faecalis infection is an opportunistic bacterial infection caused by a Gram-negative, non-fermenting rod that is normally harmless in soil and water but can colonize wounds, the urinary tract, the respiratory tract, and the bloodstream of people with breached barriers or weakened immunity. It is most often healthcare-associated, is frequently multidrug-resistant, and is treated with antibiotics guided by susceptibility testing rather than experience alone. Most localized infections resolve within 7 to 14 days with appropriate therapy. Invasive disease, especially bacteremia in immunocompromised patients, carries reported mortality approaching 20 to 30 percent in case series.
What Alcaligenes faecalis actually is
Alcaligenes faecalis is a Gram-negative, aerobic, non-fermenting bacillus first described from fecal matter, which is where the species name originates. It is motile by peritrichous flagella, oxidase-positive, and catalase-positive, and it produces a distinctively sweet, fruity odor on culture plates. That smell is one of the few bedside-useful clues, though it never substitutes for laboratory identification.
The organism is a classic opportunist rather than a primary pathogen. It survives in moist environments and can persist on hospital surfaces, in nebulizers, in dialysis water systems, and in intravenous fluid reservoirs. Between roughly 1 and 5 percent of clinical isolates from non-fermenting Gram-negative bacteria in some hospital surveys turn out to be Alcaligenes species, a reminder that it is uncommon but not reportable-rare.
Microbiologically, the key feature is its low virulence combined with high environmental durability. It rarely invades healthy tissue but readily colonizes damaged tissue. In plain terms: it is a squatter, not a burglar.
The mechanism: how colonization becomes infection
The transition from harmless colonization to true infection hinges on three factors acting together: a breached epithelial barrier, an implanted device or necrotic tissue, and impaired host immunity. Skin or mucosal injury gives the organism an entry point. Foreign material such as a catheter, stent, or prosthetic provides a surface where bacteria form a biofilm. Immunosuppression removes the phagocytic clearance that would otherwise keep the organism contained.
Biofilm formation is central. Once attached, Alcaligenes faecalis secretes an extracellular matrix that shields it from antibiotics and immune cells. Biofilm-associated bacteria can tolerate antibiotic concentrations 10 to 1,000 times higher than free-floating (planktonic) cells of the same strain. This is why device-related infections often require device removal, not just antibiotics.
The virulence arsenal is modest but relevant. The organism produces endotoxin (lipopolysaccharide), which drives fever and inflammatory signaling. Some strains show adherence factors that promote binding to respiratory and urinary epithelium. Unlike Pseudomonas aeruginosa, it lacks the broad array of toxins that make that organism so destructive. This partly explains its lower tissue invasiveness.
A non-obvious detail: Alcaligenes faecalis is intrinsically resistant to several antibiotics because of efflux pumps and low outer-membrane permeability, the same architectures seen in other non-fermenters. That intrinsic resistance is present before any treatment is given, so empirical therapy chosen for other Gram-negative infections can fail silently.
How common is it, and who is at risk
Alcaligenes faecalis infections are uncommon. In large hospital microbiology reviews, Alcaligenes species account for well under 1 percent of all clinical bacterial isolates. Among non-fermenting Gram-negative bacilli specifically, they represent a small minority behind Pseudomonas, Acinetobacter, and Stenotrophomonas.
Risk concentrates in specific groups:
- Patients with indwelling urinary catheters or venous catheters
- People with chronic wounds, burns, or surgical sites
- Patients on mechanical ventilation or with bronchiectasis
- Individuals with diabetes, cancer, or immunosuppressive therapy
- Neonates and elderly patients in intensive care
Roughly 60 to 70 percent of reported cases in case series are healthcare-associated. Community-acquired cases do occur, usually after soil or water exposure through a wound.
Clinical presentations by body site
The infection looks different depending on the portal of entry. Symptoms and typical recovery times vary by site.
| Site | Typical symptoms | Usual source | Typical duration with treatment |
|---|---|---|---|
| Wound or skin | Erythema, purulent drainage, delayed healing | Soil, water, surgical site | 7 to 14 days |
| Urinary tract | Dysuria, frequency, pyuria | Indwelling catheter | 5 to 10 days after catheter change |
| Respiratory | Cough, purulent sputum, fever | Ventilation, bronchiectasis | 10 to 14 days |
| Bloodstream | Fever, chills, hypotension | Catheter, soft tissue focus | 14 days minimum; longer if endocarditis suspected |
| Ear (otitis externa) | Itching, discharge, pain | Moisture, swimming | 7 days with topical therapy |
Bacteremia deserves special attention. In published case series, crude mortality for Alcaligenes bacteremia ranges from about 10 to 30 percent, and it is higher in patients with shock or hematologic malignancy. The organism is often a co-isolate alongside stronger pathogens, so attributing death directly to it requires clinical judgment.
Recovery timeline
The course below reflects typical uncomplicated cases treated with susceptible antibiotics and appropriate source control. Immunocompromised patients and those with retained devices run longer.
| Time point | What is happening |
|---|---|
| Day 0 | Culture obtained; empirical antibiotics started if clinically indicated |
| Day 1 to 2 | Fever often improves; preliminary culture identification |
| Day 2 to 4 | Susceptibility results guide definitive antibiotic choice |
| Day 5 to 7 | Wound or urinary symptoms improve; device removed if present |
| Day 7 to 14 | Most localized infections resolve; antibiotics completed |
| Day 14 to 21 | Bloodstream infections completed; repeat cultures if febrile |
| Week 4 to 6 | Follow-up for device-related or deep infections |
Fever that persists beyond 72 hours of appropriate therapy is a warning sign. It suggests a retained focus, a resistant strain, or a second organism.
Why this organism resists treatment
Alcaligenes faecalis is intrinsically resistant to many beta-lactams and often to aminoglycosides through chromosomal mechanisms. Acquired resistance adds to this. In surveillance reports, resistance to trimethoprim-sulfamethoxazole and to some carbapenems appears in a meaningful minority of isolates, though rates vary widely by region and are not standardized.
The practical consequence: empiric therapy chosen for a typical hospital-acquired Gram-negative infection may miss it. Susceptibility testing is not optional. Standard panels test the organism against a range of agents, and the resulting minimum inhibitory concentrations guide therapy.
There is no single universally "best" antibiotic. Clinicians choose based on the susceptibility report and the site of infection. Agents commonly active in published reports include ceftazidime, cefepime, piperacillin-tazobactam, meropenem, ciprofloxacin, and trimethoprim-sulfamethoxazole, but local resistance patterns differ. This is an established-science point, not a hypothesis: therapy must follow the isolate.
Common misconceptions, corrected
First, many people assume any positive culture means infection. It does not. Alcaligenes faecalis can be a colonizer, especially in respiratory secretions and chronic wounds. Treating colonization exposes patients to antibiotics without benefit. A positive culture plus clinical signs plus, ideally, a sterile-site specimen is a stronger basis.
Second, the organism is sometimes dismissed as "non-pathogenic environmental bacteria." That is incorrect. It can cause true disease, particularly bacteremia in immunocompromised hosts.
Third, there is a misconception that it is uniformly harmless because it is rare. Rarity is not benignity; it reflects low virulence in healthy people, not an inability to harm vulnerable ones.
Fourth, some sources conflate Alcaligenes with Achromobacter, which was historically grouped with it. They are related non-fermenters but differ in resistance profiles and clinical behavior.
Red-flag warning signs
Seek urgent medical assessment if any of the following occur:
- Fever above 100.4°F (38°C) that persists beyond 72 hours on antibiotics
- New confusion, low blood pressure, or rapid breathing in a patient with a known Alcaligenes faecalis infection
- Redness or swelling spreading rapidly around a wound
- Reduced urine output in a catheterized patient with fever
- Persistent fever after a central line has been removed
Prevention in healthcare and community settings
Prevention focuses on the same principles that limit other non-fermenters. Hand hygiene remains the single highest-value measure. Catheters should be removed as soon as they are no longer needed; every additional catheter day raises colonization risk. Wound care should keep dressings clean and dry, since the organism thrives in moisture.
For people with chronic lung disease or bronchiectasis, airway clearance techniques reduce the burden of colonizing organisms. Water systems, nebulizers, and dialysis equipment need routine disinfection. In community settings, cleaning soil-contaminated wounds promptly and thoroughly lowers risk.
In plain terms: keep devices out when possible, keep wounds clean, and keep equipment dry and disinfected.
What to actually do if infection is suspected
First, obtain a proper culture before starting antibiotics if the patient is stable. This preserves the ability to tailor therapy. For unstable patients, draw blood cultures and start empiric therapy simultaneously.
Second, request susceptibility testing on any Alcaligenes isolate from a sterile site or from a symptomatic patient. Ask specifically about carbapenem and fluoroquinolone susceptibility, since these drive choices.
Third, remove or exchange the implicated device when feasible. Biofilm makes antibiotics alone inadequate for catheter-related infection. Catheter exchange within 72 hours reduces relapse in most device-related non-fermenter infections.
Fourth, complete the full antibiotic course as prescribed, typically 7 to 14 days for localized disease and 14 days or more for bloodstream infection. Stopping early risks relapse.
Fifth, arrange follow-up culture if symptoms persist or recur. Persistent positivity suggests a retained source.
Limitations of current evidence
The evidence base for Alcaligenes faecalis is thin. Most knowledge comes from case reports and small retrospective series rather than randomized trials. Reported mortality figures vary widely because series differ in patient mix, and no large prospective studies exist. Antibiotic recommendations are therefore extrapolated from susceptibility data and broader non-fermenter literature.
This uncertainty should temper strong claims. The organism is real, capable of causing serious disease, and worth treating with precision, but the exact optimal regimens remain a matter of clinical judgment guided by local resistance data and individual susceptibility results.